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Abstract
Activation of the epithelial-mesenchymal transition (EMT) program is a critical mechanism for 
initiating cancer progression and migration. Colorectal cancers (CRCs) contain many genetic and 
epigenetic alterations that can contribute to EMT. Mutations activating the PI3K/AKT signaling 
pathway are observed in >40% of patients with CRC contributing to increased invasion and 
metastasis. Little is known about how oncogenic signaling pathways such as PI3K/AKT synergize 
with chromatin modifiers to activate the EMT program. Lysine Specific Demethylase 1 (LSD1) is 
a chromatin-modifying enzyme that is overexpressed in colorectal cancer (CRC) and enhances cell 
migration. In this study we determine that LSD1 expression is significantly elevated in CRC 
patients with mutation of the catalytic subunit of PI3K, PIK3CA, compared to CRC patients with 
WT PIK3CA. LSD1 enhances activation of the AKT kinase in CRC cells through a non-catalytic 
mechanism, acting as a scaffolding protein for the transcription-repressing CoREST complex. 
Additionally, growth of PIK3CA mutant CRC cells is uniquely dependent on LSD1. Knockdown 
or CRISPR knockout of LSD1 blocks AKT-mediated stabilization of the EMT-promoting 
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transcription factor Snail and effectively blocks AKT-mediated EMT and migration. Overall we 
uniquely demonstrate that LSD1 mediates AKT activation in response to growth factors and 
oxidative stress, and LSD1-regulated AKT activity promotes EMT-like characteristics in a subset 
of PIK3CA mutant cells.
Implications—Our data supports the hypothesis that inhibitors targeting the CoREST complex 
may be clinically effective in CRC patients harboring PIK3CA mutations.
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Introduction
Cancer cells have numerous genetic and epigenetic alterations that contribute to tumor 
formation, progression, and therapy resistance. One role of chromatin-modifying complexes 
is to maintain cellular identity by chemically modifying amino acid residues on histone and 
non-histone substrates. Lineage-specific transcriptional networks maintained by these 
complexes provide context for specific mutations which determines the phenotypic outcome 
of the mutation(1). This information can be leveraged to identify how chromatin modifiers 
synergize with specific driver mutations in tissue-specific tumor models and discover 
synthetic-lethal relationships.
Mutations in the PI3K/AKT pathway are critical for invasive properties and malignant 
transformation in colorectal cancer (CRC)(2). The two most common genetic PI3K/AKT 
pathway alterations in CRC are activating mutations in the PI3K catalytic subunit gene 
PIK3CA or loss of the pathway suppressor PTEN(3). Mutations in PIK3CA occur in 
roughly 25% of CRC patients(4) and have been functionally implicated in epithelial-to-
mesenchymal transition (EMT), migration and chemoresistance(5). While aberrant 
activation of the PI3K/AKT pathway has been implicated in CRC progression, single 
nucleotide PIK3CA mutations that activate the PI3K/AKT pathway are not significantly 
associated with alterations in patient survival(6). These findings indicate that PI3K-pathway 
activating mutations may require additional factors for full activation of the pathway. 
Recently, the lysine demethylase JMJD2A was found to be critical for steps involved in 
activation of AKT, including the recruitment of AKT to the cell membrane and 
phosphorylation of AKT at threonine 308(7, 8). These studies suggest that aberrant 
overexpression of chromatin-modifying proteins can further activate the PI3K/AKT pathway 
and therefore may work synergistically with PIK3CA mutations. Little is known with regard 
to how chromatin modifiers function in the context of PIK3CA mutation to mediate 
tumorigenic processes in the gut.
The chromatin modifier lysine specific demethylase 1 (LSD1) is overexpressed in CRC and 
positively correlates with advanced tumor staging(9). LSD1 is functionally linked to EMT-
like changes and invasion in CRC(10–12). LSD1 is a member of the RE1 silencing 
transcription factor corepressor (CoREST) complex(13), which also contains the scaffolding 
protein RCOR1 and other chromatin-modifying subunits, including histone deacetylase 1 
and 2 (HDAC1/2)(14, 15). LSD1 and HDAC1/2 within CoREST demethylate and 
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deacetylate active chromatin, respectively, to maintain a repressive chromatin state. In some 
cellular contexts, LSD1, as a member of CoREST, demethylates di-methyl Histone H3 
Lysine 4 (H3K4me2) at the promoter of epithelial genes to drive CRC(10–12). Recent 
studies, however, have highlighted catalysis-independent functions for LSD1, where it 
instead acts as a scaffold for the CoREST complex to maintain transcriptional repression of 
lineage-specific genes(16, 17). For example, RE1 silencing transcription factor (REST) can 
confine expression of neuronal genes to neuronal cells by mediating their silencing in non-
neuronal cell types through the recruitment of CoREST(14, 15, 18). Furthermore, 
mechanistic studies of LSD1 catalytic inhibitors in SCLC(19), AML(20, 21) and 
erythroleukemia(22) demonstrate that these inhibitors reactivate gene expression and alter 
processes such as survival, proliferation and differentiation by disrupting the recruitment of 
CoREST to chromatin by SNAG domain transcription factors as opposed to inhibiting LSD1 
demethylase activity. These studies further support the notion that non-catalytic LSD1 
functions are critical for tumorigenesis.
We hypothesize that LSD1 overexpression synergizes with PIK3CA mutation to enhance 
invasive phenotypes in CRC. In this study, we demonstrate that LSD1 is significantly 
overexpressed in patients harboring PIK3CA mutations in the gut, but not in cancers arising 
from other tissues. This observation is functionally significant as we demonstrate that 
PIK3CA mutant colorectal and stomach cancer cells exhibit reduced growth after 
perturbation of LSD1. We further find that LSD1 regulates activation of AKT at the level of 
phosphorylation at serine 473 and EMT characteristics downstream of active AKT through a 
non-catalytic scaffolding role in the CoREST complex. Altogether we illustrate a paradigm 
wherein LSD1 synergizes with a specific PIK3CA mutation to enhance EMT characteristics 
and migration.
Materials and Methods
Cell Culture and Treatments
All cell lines were maintained in a humidified atmosphere with 5% CO2. Our study included 
five colon cell lines (HT29, SW480, HCT116, LoVo and RKO) and one stomach cell line 
(AGS). HT29, SW480, HCT116 and LoVo cells were cultured in McCoys 5A media 
(Corning), RKO and AGS were cultured in RPMI 1640 media (Corning) supplemented with 
10% FBS (Gibco). All cell lines were purchased from the ATCC and authenticated and 
tested for Mycoplasma by IDEXX on 6/20/2019. All cells used in experiments were 
passaged fewer than 15 times with most being passaged fewer than 10 times. For H2O2 
treatments, 30% H2O2 (Sigma) was diluted in PBS immediately prior to treatment at 250 
μM for 1H at 37°C. For EGF treatments, cells were starved in media lacking serum for 48H 
prior to treatment. Cells were then treated with 100 ng/ml recombinant EGF (R&D Systems: 
236-EG) for 48H. GSK-LSD1 (Sigma, SML1072), GSK690693 (Sigma, SML0428) and 
corin (generously provided by Dr. Philip Cole and Dr. Jay Kalin) were solubilized in DMSO 
(Sigma) prior to treatment. Treatment dosages and durations are defined in the figure 
legends.
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Knockdown, Knockout and Transient Transfections
LSD1 (KDM1A) (TRCN0000327856), RCOR1 (TRCN0000128570) and HDAC1 
(TRCN0000195467, TRCN0000195103) knockdown constructs were purchased from Sigma 
Aldrich mission shRNA; empty plasmid was used as a vector control. Lentiviral-mediated 
knockdowns were performed as previously described(23). CRISPR/Cas9 LSD1 KO plasmid 
(sc-430289) and LSD1 HDR plasmid (sc-430289-HDR) were purchased from Santa Cruz 
and knockout was performed according to manufacturer’s protocol. Individual LSD1 KO 
clones were isolated for experiments, or mixed population KO’s were used, as defined in the 
figure legends. Cells were transfected with Lipofectamine 3000 (Invitrogen) per the 
manufacturer’s protocol. N-terminus HA tagged LSD1 plasmid was purchased from Sino 
Biological (HG13721-NY) with pCMV3-N-HA used as a negative control vector.
Site-directed Mutagenesis
Mutagenesis was performed according to manufacturer’s protocol (NEB, E0554) using HA-
LSD1 plasmid as template, and confirmed via Sanger sequencing by Eurofins Scientific. 






ChIP was performed using Diagenode iDeal ChIP-seq kit (C01010055 - for Transcription 
factors) (C01010057 - for histone modifications) per manufacturer’s protocol. Libraries 
were generated for sequencing using the NEBNext Ultra DNA Library Prep Kit for Illumina 
(NEB) per manufacturer’s protocol.
Chromatin Bound Fraction and Whole Cell Isolation
Chromatin bound (or tight chromatin) fractions were isolated as previously described(23). 
For protein isolation, cell pellets were lysed in 4% SDS buffer using a Qiashredder (Qiagen). 
Relative densitometry for western blots were determined using ImageJ software, and 
normalized to density of loading controls Lamin-B, β-Actin or Histone H3. All antibodies 
used in this study are included in the Supplementary Materials and Methods.
Immunofluorescence and Imaging
2 × 105 HT29 cells were grown on coverslips at 37°C. After 48 hours, they were treated with 
250μM H2O2 for 1 hour. The cells were then fixed with 4% paraformaldehyde in PBS for 15 
minutes at RT. Cells were permeabilized with 0.5% Triton-X in PBS for 10 minutes at RT 
and then fixed with 1% BSA in PBST (PBS + 0.2% tween 20) for 30 minutes. They were 
then incubated with anti-LSD1 (1:100) and anti-pAKT (1:100) in 1% BSA in PBST for 1 
hour at RT. This was followed by incubation with Alexa flour anti-rabbit 594 (1:500) and 
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Alexa flour anti-mouse 488 (1:1000) for 1 hour at RT. Coverslips were mounted using 
prolong gold antifade with DAPI molecular probes (CST #8961). Images were acquired 
using Leica SP8 confocal microscope at a magnification of 63X. The NA of 63X objective 
used is 1.4. Images were processed using Image J.
Proliferation Assays
Assays were performed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega 
#G7572) per manufacturer’s protocol. Briefly, 1×10^3 cells were plated in 96 well plates 
and allowed to incubate under standard growth conditions. Luminescent signals were 
detected on a SYNERGY H1 microplate reader (BioTek) using Gen 5 software (v2.09). All 
plate readings were normalized to a control plate to account for variance in plating density.
Clonogenic Growth and Migration Assays
500 (HT29) or 1500 (SW480) single cells were plated and allowed to culture at 37°C. After 
10 days, cells were fixed with 10% formalin and stained with crystal violet. Crystal violet 
stained cells were imaged using a SYNGENE G:BOX and quantified using the GeneSys and 
GeneTools programs. For migration, 7.5 × 10^4 cells in serum free media were plated into 
transwell in 24 well plates (corning #40578) for 48H with media containing 10% FBS at the 
bottom. Transwell inserts were stained using Hema 3 Stat Pack (Fisher #123–869). 
Migration inserts were randomized prior to manual quantification and the outer 5% of the 
inserts were not included during quantification to reduce edge-effect bias. All images were 
taken on an EVOS FL Auto microscope.
RNA Isolation for RNA-sequencing and Quantitative PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen, 74104). For RNA-sequencing of 
empty vector and LSD1 knockdown cells, libraries were generated using Illumina TruSeq 
Stranded mRNA (Illumina, 20020594), or as previously described for RNA-sequencing of 
DMSO and GSK-LSD1 treated cells(24). For qPCR, RNA was used to generate cDNA via 
reverse transcription (Thermo, K1642). cDNA was amplified using gene-specific primers 
and FastStart Essential DNA Green Master (Roche, 06402712001). Cq values of non-
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Sequencing, TCGA and Statistical Analyses
Detailed description included in the Supplementary Materials and Methods. All experiments 
were performed in biological triplicate unless otherwise specified, with representative results 
displayed. All quantitative plots depict mean ± SD unless otherwise stated.
Data availability
RNA-sequencing and ChIP-sequencing data have been deposited in NCBI’s Gene 
Expression Omnibus and are accessible through GEO Series accession number GSE139927.
Results
Knockdown of LSD1 reduces phosphorylation of AKT S473
To initially determine if LSD1 works synergistically with PIK3CA, we analyzed The Cancer 
Genome Atlas (TCGA) patient data from 7 different cancer types where PIK3CA mutations 
are common. LSD1 expression was significantly higher in PIK3CA mutant versus WT 
tumors for gastrointestinal cancers colon adenocarcinoma (COAD) and stomach 
adenocarcinoma (STAD) (Figure 1A). There was a trend toward increased LSD1 expression 
in PIK3CA mutant rectal adenocarcinomas (READ) in the modest number of cases 
analyzed. All other tumor types either had no significant change (BLCA, LUSC) or a 
significant decrease (BRCA, HNSC) in LSD1 expression in the presence of a PIK3CA 
mutation compared to PIK3CA WT tumors.
The PI3K pathway has been extensively shown to mediate signaling through the activation 
of AKT. AKT is synergistically activated(25) by phosphorylation of threonine 308 by 
PDK1(26), and serine 473 mediated by mTORC2 as part of the mTORC/Rictor 
complex(27). Chromatin modifiers, specifically histone demethylating enzymes, have 
recently been linked to the regulation of AKT phosphorylation(7, 8). Therefore, we wanted 
to test the hypothesis that LSD1 may be a mediator of complete AKT activation. shRNA-
mediated knockdown (KD) of LSD1 resulted in a significant reduction in pS473-AKT 
relative to EV cells in both HT29 and SW480 CRC cell lines (Figure 1B,C). There was no 
significant change in pT308-AKT in LSD1 KD SW480 cells and we were unable to detect 
pT308-AKT in HT29 cells, potentially due to low sensitivity. To confirm the effect of LSD1 
on pS473-AKT, we used CRISPR to generate two LSD1 knockout (KO) clones each in the 
SW480 and HT29 cell lines. KO of LSD1 also resulted in reduction of pS473-AKT (Figure 
1D, E). Importantly, re-introduction of LSD1 was sufficient to rescue pS473-AKT levels in 
both cell lines (Figure 1D, E). To test the function of LSD1 in de-novo activation of AKT, 
we stimulated pS473-AKT using hydrogen peroxide (H2O2)(28). LSD1 KD blocked H2O2-
dependent pS473-AKT and, conversely, overexpression of LSD1 enhanced H2O2-dependent 
pS473-AKT (Figure 1F). Overexpression of LSD1 in combination with H2O2 reduced total 
AKT, potentially due to a feedback mechanism associated with hyper-phosphorylation of 
AKT, as has been shown with some AKT inhibitors(29). LSD1-mediated regulation of 
pS473-AKT observed by western blot was confirmed by immunofluorescence under both 
basal and H2O2-treated conditions (Figure 1G). pS473-AKT was reduced in LSD1 KD cells 
compared to empty vector. LSD1 deficient cells exhibited no change in pS473-AKT after 
H2O2 treatment, while LSD1 proficient cells exhibited H2O2-induced pS473-AKT. To test 
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the alternative hypothesis that mutant PIK3CA was directly causing increased LSD1 
expression, we inhibited PI3K in PIK3CA mutant CRC cells, but saw no change in LSD1 
levels (Supplementary Figure S1). Together these results demonstrate that LSD1 is more 
highly expressed in PIK3CA mutant CRC compared to WT PIK3CA CRC and that LSD1 
levels positively correlate with pS473-AKT, highlighting a molecular connection between 
LSD1 levels and activation of the PI3K/AKT pathway.
LSD1 catalytic activity is not required for its regulation of pS473-AKT
LSD1 catalyzes demethylation of mono- and di-methylated lysine residues on histone(13) 
and non-histone substrates(30). The oncogenic function of LSD1 in CRC has previously 
been attributed to its ability to demethylate H3K4me2 at the promoter of epithelial genes, 
causing their repression and promoting more aggressive cellular phenotypes via enhanced 
EMT(11, 12). In contrast, newly emerging research has documented non-catalytic oncogenic 
functions of LSD1(16, 17, 19–22) and suggests we need to consider LSD1 enzymatic 
activity in the regulation of AKT activation. To address this, we first performed ChIP-seq of 
LSD1 in SW480 cells to identify direct binding targets genome-wide, generating a catalog of 
potential catalytic target loci. Consistent with other studies, LSD1 enrichment at genes was 
primarily detected near transcription start sites (TSS)(31) (Figure 2A). To generate a list of 
potential LSD1 targets de novo and confirm the specificity of our antibody, LSD1 peaks 
were called by normalizing LSD1 enrichment in parental cells to our LSD1 CRISPR KO. 
We detected 6,221 LSD1 peaks shared between replicates. Using DNase sequencing data 
from the SW480 cell line, we observed depletion of DNase cleavage centered at LSD1 peaks 
genome-wide (Figure 2B), confirming occupancy of these regions. This DNase footprint is 
not an artifact of LSD1 enrichment at TSSs, as we do not observe an overall depletion of 
DNase cleavages over TSSs (Supplementary Figure S2A). To determine if LSD1 KD alters 
genome-wide histone methylation status, we performed ChIP-seq for the LSD1 substrate 
H3K4me2 in control and LSD1 KD SW480 cells. There was a slight decrease in H3K4me2 
enrichment genome-wide after LSD1 KD, in contrast to the increase that would be expected 
based on LSD1’s known histone demethylase activity (Figure 2C). There was no significant 
change in bulk H3K4me2 after LSD1 KD suggesting the slight change in ChIP-seq may not 
be biologically relevant (Supplementary Figure S2B). To identify potential direct 
transcriptional targets of LSD1, we performed RNA-seq after LSD1 KD in SW480 cells. We 
combined this transcriptional data with our ChIP-seq datasets to assess H3K4me2 levels at 
genes with LSD1 enrichment near their promoters and significantly increased expression 
after LSD1 KD. The promoter regions of genes FBN3, TRPM6, and RASD2 are depicted as 
representative loci for this analysis. There were no significant changes in H3K4me2 
enrichment at the promoter of FBN3, TRPM6, or RASD2 (Figure 2D), nor at the promoter 
of any gene following LSD1 KD (data not shown). CDH1, a published target of LSD1, 
showed significantly increased gene expression (log2FC=1.070, FDR=0.035) after LSD1 
KD. However, there was no change in H3K4me2 at the CDH1 promoter after LSD1 KD, nor 
did we detect enrichment of LSD1. A recent study in PC3 prostate cancer cells demonstrated 
similar results, wherein levels of H3K4me2 following LSD1 KD only changed at the 
promoter of 2 genes(16). Together, these data suggest that LSD1 impacts gene expression in 
SW480 colon cells without demethylating H3K4me2.
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To further characterize LSD1’s role in SW480 cells, we treated these cells with a highly 
potent and selective inhibitor, GSK-LSD1(31) and performed RNA-sequencing. Treatment 
with this small molecule had a minimal effect on gene expression (0 genes with expression 
significantly altered >Log2FC=1), whereas LSD1 KD caused robust activation of gene 
expression, consistent with the role of LSD1 as a transcriptional repressor (Figure 2E). 
Additionally, while H2O2 treatment induced the expected increases in pS473-AKT, 
inhibiting LSD1 did not significantly alter basal or H2O2-induced pS473-AKT levels (Figure 
2F), with similar results in HT29 cells (Supplementary Figure S2C). Moreover, catalytically 
defective K661A mutant LSD1 was able to rescue pS473-AKT levels in LSD1 KO HT29 
cells similarly to WT LSD1, both basally and in response to H2O2 (Figure 2G). Together 
these studies strongly support the concept that LSD1-mediated transcriptional repression and 
regulation of AKT-activation are independent of LSD1 catalytic activity in these CRC cell 
lines.
LSD1 regulates pS473-AKT by scaffolding the CoREST complex on chromatin
Our RNA- and ChIP-seq data suggest that LSD1-mediated regulation of AKT-activation is 
independent of demethylase activity; we therefore hypothesized that this regulation may 
instead occur through LSD1’s stabilizing role in the repressive CoREST complex. To 
address this, we performed a chromatin fractionation assay. KD of LSD1 in SW480 cells led 
to a significant decrease in whole cell and chromatin bound levels of the CoREST scaffold 
protein RCOR1 (Figure 3A). HDAC1 and HDAC2 can be recruited to assist in the repressive 
functions of CoREST complexes(32). While whole cell levels of HDAC1/HDAC2 remain 
unchanged after LSD1 KD, there is a significant reduction in the chromatin binding of 
HDAC1 (Figure 3A). This result supports the notion that loss of LSD1 reduces formation of 
the CoREST complex and therefore reduces HDAC1 recruitment to chromatin. This is 
consistent with a recent study, where loss of LSD1 decreased HDAC1 binding at LSD1-
enriched enhancers in leukemia cells(20). There was a slight but insignificant decrease in the 
recruitment of HDAC2 to chromatin (Figure 3A). It is possible that a smaller proportion of 
cellular HDAC2 is recruited to CoREST complexes in comparison to HDAC1. RCOR1 is 
one of three CoREST isoforms that interact with LSD1(33). RCOR contains a SANT 
domain which enhances the complex’s interaction with histones and therefore plays an 
important scaffolding role for the CoREST complex(34). To determine whether the CoREST 
complex functions in the regulation of AKT activation, we performed KD of RCOR1 using 
shRNA and induced pS473-AKT using H2O2. KD of RCOR1 in HT29 cells reduced basal 
levels of pS473-AKT and blocked H2O2-induced pS473-AKT (Figure 3B). Additionally, 
there was a decrease in whole cell levels of LSD1 protein, consistent with the scaffolding 
function ascribed to RCOR1 (Figure 3B).
To our knowledge, HDAC1 does not function as a scaffold in the CoREST complex but 
instead contributes to the formation of a repressive chromatin environment by catalyzing the 
removal of acetyl groups from histone lysine residues. To determine if loss of HDAC1 alone 
is sufficient to block AKT activation, we knocked down HDAC1 using two independent 
shRNAs and stimulated AKT using H2O2. HDAC1 KD had no effect on H2O2-induced 
pS473-AKT or whole cell levels of LSD1 in HT29 (Figure 3C) or SW480 cells 
(Supplementary Figure S3A). Overall, knockdowns of proteins that stabilize the CoREST 
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complex (LSD1 or RCOR1) were sufficient to perturb AKT activation while knockdown of 
a protein (HDAC1) that interacts with the core CoREST complex had no effect on AKT 
activation, indicating that an intact, chromatin-associated core CoREST complex is required 
for full activation of AKT.
Recently, a single molecule hybrid inhibitor targeting multiple chromatin modifiers within 
the CoREST complex was synthesized. The compound corin contains an LSD1 inhibitor 
(tranylcypromine analog) fused to a class 1 HDAC inhibitor (MS-275) and exhibits near 
irreversible inhibition of the CoREST complex(35) (Figure 3D). In vitro and cellular studies 
demonstrated this compound is selective for complexes containing HDAC1 and LSD1 over 
complexes that only contain HDAC1. Corin treatment led to a dose-dependent reduction in 
pS473-AKT, with the effect increasing over time (Figure 3E). Consistent with HDAC1 
inhibition, global H3K9Ac levels increased after treatment with corin. At similar 
concentrations, MS-275 alone does not reduce pS473-AKT(36).
To test whether these observations mirror the patient data available through the TCGA, we 
investigated RCOR1 expression in PIK3CA WT and mutant tumors. Like LSD1, RCOR1 
showed significantly higher levels of expression in PIK3CA mutant compared to WT in GI 
cancer types COAD, READ and STAD (Figure 3F). Generally, there was no significant 
association between RCOR1 expression and PIK3CA mutation in non-GI cancer types 
(Supplementary Figure S3B). However, there was no significant correlation observed 
between LSD1 and RCOR1 expression in COAD and READ datasets but there was a 
significant correlation in the STAD dataset (Supplementary Figure S3C). Consistent with the 
idea that only LSD1 or RCOR1 need to be overexpressed to stabilize the other, high 
expression of LSD1 or RCOR1 in COADREAD patient data was significantly associated 
with PIK3CA mutation compared to patients with low expression of both LSD1 and 
RCOR1, and the magnitude of change was significantly greater than expected by random 
chance from permutation testing (Figure 3G). Altogether these data suggest that LSD1 
regulates AKT activation through a scaffolding function for the CoREST complex. An intact 
chromatin-bound CoREST complex is required to mediate positive regulation of AKT 
activation via regulation of gene expression. Furthermore, high expression of CoREST core 
members LSD1 or RCOR1 is significantly associated with the presence of PIK3CA 
mutation.
LSD1 regulates EMT-associated gene programs in PIK3CA mutant cells
Based on our observations from clinical datasets (Figure 1A), we tested a phenotypic link 
between PIK3CA mutational status and cellular levels of LSD1. We selected six cell lines 
for this analysis: five colon cancer lines (SW480, HT29, LoVo, HCT116, and RKO) and one 
stomach cancer line (AGS). SW480 and LoVo are PIK3CA WT, whereas HT29, AGS, 
HCT116, and RKO all carry PI3K-activating PIK3CA mutation(s). The cell lines selected 
have several other common CRC mutations but none are unique to the PIK3CA mutant or 
WT cells (Supplementary Table S1)(37). LSD1 KD had no effect on the growth of PIK3CA 
WT cell lines (Figure 4A). Interestingly, LSD1 KD caused a significant reduction in growth 
in all PIK3CA mutant cell lines. Similar results were obtained with LSD1 CRISPR 
knockout, where LSD1 KO significantly reduced growth in PIK3CA mutant HT29 cells, but 
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had no effect on the growth of PIK3CA WT SW480 cells (Supplementary Figure S4A–D). 
These data suggest that PIK3CA mutant cancers may be sensitive to targeting of LSD1, and 
raise the unique possibility that LSD1 may be important for the tumorigenic activity of 
PIK3CA mutations.
Since perturbing LSD1 abrogates activation of AKT in both HT29 (PIK3CA mutant) and 
SW480 (PIK3CA WT) cells but only reduces the viability of HT29 cells, we hypothesized 
that AKT may be uniquely targeting pathways associated with cell survival in HT29 but not 
SW480 cells. To test this hypothesis, we performed RNA-seq in the EV and LSD1 KD 
HT29 cells and generated datasets that consisted of genes with significantly altered 
expression in LSD1 KD versus EV for each cell line. When comparing these two datasets, 
there was very little overlap between genes upregulated by LSD1 KD, exemplified by a 
weak positive correlation (R2=0.121), suggesting that the majority of significant changes 
were unique between the two cell lines (Figure 4B). The largest set of genes with 
significantly altered expression after LSD KD compared to EV by >3-fold was genes 
uniquely upregulated in HT29 cells. The only commonly downregulated gene between the 
datasets was LSD1, further validating the specificity of our KD. To identify conserved and 
divergent characteristics between the two datasets, we performed gene set enrichment 
analysis (Figure 4C). As validation, genes upregulated after LSD1 KD in an independent 
dataset were enriched and upregulated by LSD1 KD in both HT29 and SW480 cells as 
determined by RNA-seq. In agreement with our finding that LSD1 KD reduces recruitment 
of HDACs to chromatin, genes downregulated after HDAC1 and HDAC2 overexpression 
were also significantly enriched and upregulated in our data. In support of our finding that 
LSD1 is critical for AKT activation, genes upregulated during active PI3K/AKT signaling 
were significantly enriched in our HT29 dataset, and trended towards downregulated after 
LSD1 KD in both SW480 and HT29 RNA-seq datasets, indicating reduced active AKT 
signaling. 65 PI3K/AKT signaling genes were downregulated between the two cell lines. 
While 51% were commonly downregulated, 69% of the remaining genes were uniquely 
downregulated in HT29 cells indicating LSD1 KD may have a more significant effect on 
gene expression in this pathway in HT29 cells. Further, by gene ontology analysis of genes 
uniquely upregulated after LSD1 KD in SW480 cells no enriched genesets were associated 
with proliferation indicating that there is likely not a compensatory pathway activated in 
SW480 cells to buffer loss of AKT activation (Supplementary Figure S4E). Additionally, 
genes downregulated by TGFβ1 were enriched and upregulated in HT29 cells after LSD1 
KD (Figure 4C). This is interesting since cross-talk between the PI3K/AKT and TGF-β 
signaling networks plays a critical role in tumor progression(38).
We next narrowed our focus to genes that were uniquely upregulated in the HT29 cells after 
LSD1 KD (N=523) and performed hypergeometric enrichment analysis using the Reactome 
database. In agreement with another study in CRC cells, ontologies associated with immune 
response were enriched(39). We additionally identified pathways associated with 
extracellular matrix organization and cellular junction organization, one example being the 
formation of hemidesmosomes, which play a role in epithelial cell adherence to extracellular 
matrices and are lost during EMT(40) (Figure 4D). Among genes uniquely downregulated 
after LSD1 KD in HT29 cells, were mediators of EMT-associated elastic fibre formation, 
TGFB3 and LOXL1 (data not shown). Together these data suggest that LSD1 regulates EMT 
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characteristics in HT29 cells. Clonogenic assays test the ability of a tumor cell to survive 
and grow in isolation, an important characteristic of EMT and stem-like cells, which may be 
a critical attribute for metastasis(41, 42). HT29 cells exhibited > 7-fold reduction in 
clonogenic survival after LSD1 KD, while there was no significant loss of clonogenic 
survival in PIK3CA WT SW480 cells (Figure 4E). Together this data demonstrates that 
LSD1 KD causes a significant reduction in growth and survival as well as alterations in gene 
expression programs related to EMT in PIK3CA mutant but not PIK3CA WT CRC cell 
lines.
LSD1 regulates protein stability of Snail through regulation of AKT
AKT has been extensively implicated in the EMT process through protein stabilization of 
the EMT-promoting transcription factor Snail family Transcriptional Repressor 1 (SNAI1 or 
Snail). Snail can be phosphorylated by GSK3β leading to its ubiquitination and subsequent 
proteasomal degradation(43). Active AKT can phosphorylate GSK3β at serine 9(44), 
inhibiting its kinase activity toward Snail, and increasing the protein half-life of Snail. 
However, the cellular contexts that support the AKT-GSK3β-Snail axis are not well 
understood. While the downstream functional outcomes of PIK3CA mutations in different 
domains are poorly characterized, one study suggests they may alter different downstream 
pathways, and require unique co-factors to exert their oncogenic effects(45). Further, 
PIK3CA mutations in the p85, C2, helical and kinase domains all increase PIK3CA lipid 
kinase activity, but only mutations in C2, helical and kinase domains are sufficient to 
robustly increase pS473-AKT and transform cells(46). The exact functions of C2 domain 
mutations in driving tumorigenesis have remained largely uncharacterized, as researchers 
have focused primarily on more commonly occurring kinase and helical domain mutations. 
We hypothesize that the activity of the AKT-GSK3β-Snail axis in CRC cells is dependent on 
the PIK3CA mutational status.
To test for the effect of PIK3CA mutational status on AKT-mediated stabilization of Snail 
protein, we inhibited AKT across our cell line panel using a potent and selective competitive 
pan-AKT inhibitor, GSK690693(29). Treating cells with this inhibitor generates a feedback 
that causes hyper-phosphorylation of S473-AKT, reduction of AKT protein levels, and loss 
of pS9-GSK3β. Inhibiting AKT did not change or caused an increase in Snail protein levels 
in PIK3CA WT (SW480/LoVo) or PIK3CA kinase mutant (HCT116/RKO) cells, 
respectively (Supplementary Figure S5A–D). Inhibiting AKT in PIK3CA C2 (HT29) or C2 
and helical (AGS) mutant cells led to a marked decrease in the protein levels of Snail (Figure 
5A, B) independent of significant changes in the mRNA levels of Snail (Figure 5C). Using 
the TCGA pancancer datasets, we stratified seven different cancer types based on the 
domain frequency of PIK3CA mutations (Figure 5D). While mutations in the C2 domain 
represented on average 10.6% of PIK3CA mutations across the different cancer types, 
mutations in GI cancers of the stomach and colon/rectum were disproportionately higher at 
22.2% and 14%, respectively. Together these results suggest that activation of the AKT-
GSK3β-Snail axis may depend on PIK3CA mutational status and correlates with mutations 
in the C2 domain which are more prevalent in some GI cancers.
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We next sought to determine if LSD1 enhances EMT-like changes in HT29 cells through 
positive regulation of the AKT-GSK3β-Snail axis. LSD1 KD resulted in a strong reduction 
in Snail protein levels (Figure 5E) that was independent of significant changes in SNAI1 
mRNA (Figure 5F). As expected, changes in Snail protein level were accompanied by 
decreases in pS473-AKT and pS9-GSK3β. Treatment of cells with proteasome inhibitor 
MG-132 was sufficient to rescue Snail protein levels after LSD1 KD (Figure 5E). While re-
expression of LSD1 in LSD1 KD cells was sufficient to rescue protein levels of Snail, re-
expressing LSD1 in the context of AKT inhibition was not sufficient to rescue Snail protein 
levels, further supporting our hypothesis that LSD1 is acting upstream of AKT in the 
stabilization of Snail (Figure 5G). LSD1 did not significantly effect AKT activation in AGS 
cells nor did LSD1 KD significantly reduce Snail protein level, supporting the notion that 
LSD1-mediated changes in Snail protein rely on LSD1 regulation of AKT (Supplementary 
Figure S5E). While LSD1 KD reduced pS473-AKT in SW480 cells, LSD1 KD had no 
significant effect on Snail protein level (Supplementary Figure S5F). This result is consistent 
with our finding that inhibiting AKT has no effect on Snail protein in this cell line 
(Supplementary Figure S5A). In additional cell lines with WT (LoVo) or kinase domain 
(RKO, HCT116) mutant PIK3CA where AKT inhibition did not alter Snail levels 
(Supplementary Figure S5B–D), LSD1 KD did not alter pS473-AKT levels, further 
suggesting this axis is mutation-dependent (Supplementary Figure S5G–I). Together these 
data indicate PIK3CA C2 domain mutations may function in the activation of the AKT-
GSK3β-Snail axis. Furthermore, our molecular studies establish LSD1 as a context-
dependent upstream regulator of this pathway.
The CRC Subtyping Consortium has previously developed a classifier that can be used to 
subtype cancers into 4 groups CMS1 (MSI/immune), CMS2 (canonical), CMS3 (metabolic) 
and CMS4 (mesenchymal) (47). While there was no significant difference in LSD1 
expression between CMS1-CMS4 subtyped COADREAD datasets, LSD1 was uniquely 
upregulated (P < 0.05) in PIK3CA mutant CMS4 mesenchymal subtype tumors compared to 
WT (Supplementary Figure S6A, B). This finding suggests our observation that LSD1 is 
overexpressed in PIK3CA mutant vs. WT CRC tumors (Figure 1A) is at least in part 
explained by significant differences in CMS4 subtyped tumors. Further, we found that 
PIK3CA C2 domain mutations were most common in CMS4 subtyped tumors 
(Supplementary Figure S6C). This observation in addition to our AKT inhibitor studies 
established a connection between PIK3CA C2 domain mutations and mesenchymal 
phenotypes.
LSD1 is required for EGF-induced migration in HT29 cells
EGF has previously been used to enhance migratory phenotypes through the AKT-GSK3β-
Snail axis(48). HT29 cells exhibited little to no basal migration, but upon stimulation with 
EGF, exhibited a significant >30 fold increase in migration (Figure 6A, B). Importantly, loss 
of LSD1, inhibition of AKT or inhibition of the CoREST complex completely blocked EGF-
induced migration (Figure 6A, B). Treatment with EGF altered HT29 cellular morphology, 
with cells becoming elongated and scattered; however, LSD1 KO abrogated EGF-mediated 
changes in cellular morphology (Supplementary Figure S7). Treatment of cells with EGF led 
to an increase in levels of pS473-AKT, pS9-GSK3β and Snail at 24H and 48H (Figure 6C). 
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LSD1 KD completely blocked EGF-induced activation of pS473-AKT, pS9-GSK3β and 
increase in Snail protein. LSD1 KD also increased levels of the epithelial marker Claudin-1. 
Together these data suggest that LSD1 is required for EGF-induced migration mediated by 
the AKT-GSK3β-Snail pathway.
Discussion
In this study, we implicate LSD1 in the regulation of AKT activity. We find that PIK3CA 
mutant CRC cell lines are sensitive to LSD1 KD whereas WT cells are not. Using TCGA 
data, we provide evidence that this connection between LSD1 and PIK3CA mutation status 
may be unique to gastrointestinal tumor types. PI3K inhibitors, which have been successful 
in gynecological and breast cancers with mutant PIK3CA, have failed in CRC clinical trials, 
suggesting that additional factors influence the PI3K pathway in CRC. We demonstrate for 
the first time that LSD1 regulates basal AKT activation as well as activation in response to 
both exogenous oxidative stress and growth factors and, in a subset of PIK3CA mutant cells, 
LSD1-mediated AKT activity promotes EMT-like characteristics, including migration.
Our findings suggest that LSD1 may play a role in the full activation of AKT. We highlight, 
for the first time, an oncogenic function for LSD1 in the regulation of PI3K/AKT signaling 
via catalytically independent regulation of gene expression. We hypothesize that the 
CoREST complex represses gene(s) that normally function to regulate S473-AKT 
phosphorylation such as regulators of cell receptors, negative regulators of upstream kinases 
and/or phosphatases. When the complex is disrupted, these gene(s) are expressed and 
perturb AKT phosphorylation. Our RNA-seq data in HT29 cells confirms that LSD1 KD 
decreases PI3K/AKT pathway activity. However, it is unclear from these datasets how S473-
AKT phosphorylation is regulated. Future studies will determine the mechanisms by which 
CoREST complexes influence pS473-AKT.
The canonical function of LSD1 is to catalyze the demethylation of histones to repress gene 
expression(13). Previously, a study has shown using endometrial cancer cells that during 
estrogen signaling, PI3K/AKT upregulated LSD1 protein levels and LSD1 sustained this 
process through the demethylation of histones to activate gene expression, thereby creating a 
positive feedback loop(49). Our study presents a model that is in contrast to a classical 
enzymatic role for LSD1 as we establish a catalytically independent oncogenic function for 
LSD1 both in the regulation of PI3K/AKT signaling and in the regulation of gene expression 
without the requirement of nuclear hormone signaling. Furthermore, according to our gene 
expression data obtained from RNA-seq of LSD1 KD cells, we detected significant increase 
in CDH1 gene expression after LSD1 KD. The change in CDH1 expression after LSD1 KD 
is consistent with previous studies, including studies performed in HCT116 cells, that 
demonstrate LSD1 is recruited by Snail to the promoter of E-cadherin (CDH1) to 
demethylate H3K4me2 to repress CDH1 gene expression and drive EMT and migration(10–
12). However, there was no change in H3K4me2 at the CDH1 promoter after LSD1 KD or 
enrichment of LSD1 in our SW480 cells. This result suggests that regulation of CDH1 gene 
expression occurs through an alternative mechanism that is independent of LSD1 enzymatic 
activity in some CRC cell lines. Our findings are unique from studies where LSD1 interacts 
with Snail to promote migration through its demethylase activity in that we demonstrate 
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LSD1 promotes survival and migration through stabilization of Snail by a non-catalytic 
activity. This is a critical distinction because as inhibitors of LSD1 advance in clinical trials, 
it is crucial to establish the importance of the enzymatic versus scaffolding activity of LSD1, 
as its tumorigenicity may be dynamic between CRC tumors or even within tumor cell 
populations. This information will enable us to determine how LSD1 may be acting in a 
particular tumor and inform patient enrollment in future clinical studies.
Our study demonstrates that the activation of AKT in CRC cells depends on the scaffolding 
function of LSD1 in the CoREST complex. In agreement with our findings, a recent study 
demonstrated that a demethylase dead mutant LSD1 was able to rescue viability defects in 
lymphoma cells where LSD1 had been knocked down (17). This study further demonstrated 
that an LSD1 mutant unable to interact with CoREST was not sufficient to rescue viability 
defects induced by LSD1 KD. In our study, we also demonstrate that the dual LSD1/HDAC1 
inhibitor corin was sufficient to ablate pS473-AKT, mimicking our KD and CRISPR studies. 
It is tempting to speculate that corin, rather than acting through inhibiting enzymatic activity, 
co-binds to LSD1 and HDAC1, disrupts the complex’s histone-interacting surface, and 
reduces the complex’s interaction with chromatin, as has been shown with other LSD1 
inhibitors(19–22). The finding that LSD1 and RCOR1 correlate in STAD, but not COAD or 
READ may reflect differences in how these genes are transcriptionally regulated between 
the large intestine and stomach. LSD1 and RCOR1 are stabilized through their protein-
protein interactions with one another, (50) consistent with our observation that loss of LSD1 
decreases RCOR1 protein and vice versa (Figure 3A, B). This association also suggests that 
only LSD1 or RCOR1 needs to be overexpressed to increase protein levels of the other. Our 
finding that HDAC1 KD did not phenocopy loss of LSD1 or RCOR1 in the regulation of 
pS473-AKT supports this conjecture, but the possibility remains that corin may function 
through enhanced repression of HDAC1 in CoREST complexes.
PI3K/AKT signaling is essential for gut development due to its role in the activation of EMT 
and extracellular matrix (ECM)-modifications that lead to the specification of foregut 
precursors(51). Interestingly, we demonstrate that LSD1 plays a significant role in the 
regulation of ECM organization and EMT-associated gene expression programs. It is 
possible that LSD1 and PI3K signaling may cooperate during specification of foregut 
precursors. This hypothesis may also explain why there is a positive association between 
CoREST expression in PIK3CA mutant GI cancers but not in other cancer types, suggesting 
that this interaction may be lineage dependent. It is also consistent with our observation of 
EMT-associated gene expression programs in a CRC cell line harboring PIK3CA mutation 
within the C2 domain.
In our TCGA analyses of PIK3CA mutation frequencies, mutations in the helical and kinase 
domains were most frequent across the different cancer types while less common mutations 
such as those in the C2 domain, RBD and ABD appeared more cancer specific. Mutations in 
the C2 domain were disproportionately more common in GI cancers of the stomach and 
colon/rectum. The exact nature of the relationship between PIK3CA mutation and LSD1 
expression is currently unclear, and further studies are required. It is possible that LSD1 
expression is more closely linked to specific PIK3CA mutations, and that the prevalence of 
the specific mutation in a given cancer type is driving the significance of the association 
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between LSD1 expression and PIK3CA mutational status in the TCGA data. Our study also 
suggests that activation of the AKT-GSK3β-Snail axis to promote EMT may be dependent 
on PIK3CA C2 domain mutation. This mechanism for upregulation of Snail is different from 
a previously described mechanism by which PIK3CA with the H1047R kinase mutation 
upregulates SNAI1 mRNA expression(52). Further, our finding of AKT-signaling dependent 
Snail stabilization by LSD1 is a distinct mechanism from stabilization of Snail through 
interaction with the CoREST complex(10). An important caveat to our PIK3CA mutational 
studies is that AGS cells contain mutations in both the C2 and helical domains of PIK3CA. 
Our study does not dissect whether helical domain mutations alone are associated with the 
AKT-GSK3β-Snail axis. Future studies are required to untangle the functional role of 
different PIK3CA mutations and to establish a mechanistic understanding of their 
differential roles in mediating the AKT-GSK3β-Snail axis. While we focus on the 
interaction between LSD1 and PIK3CA C2 domain mutation, we also demonstrated that 
LSD1 KD reduced proliferation of cell lines with PIK3CA kinase domain mutations. It will 
be important to study LSD1 under the context of different PIK3CA mutations in order to 
potentially identify a synthetic lethal relationship and establish prognostic value in GI 
cancers.
Herein, we used EGF as tool to induce migration of HT29 cells. The tumor 
microenvironment plays a critical role in promoting EMT via autocrine and paracrine 
signaling by growth factors such as EGF, which stimulates EMT and migratory phenotypes 
in tumor cells (53). Further in vivo studies are required to understand how LSD1 may 
regulate signaling events between tumors and the surrounding microenvironment.
Overall we propose a model where the CoREST complex can act synergistically with C2 
domain PIK3CA mutations and growth factors to fully active the PI3K/AKT pathway and 
stabilize Snail protein to enhance cell migration and survival (Figure 6D). Genetic or 
therapeutic perturbation of the CoREST complex is sufficient to block cancer cell migration 
and reduce survival. This work suggests that PIK3CA mutant CRC may be particularly 
sensitive to LSD1 inhibitors that block the interaction of CoREST with transcription factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: LSD1 regulates phosphorylation of AKT in CRC.
(A) Box and whisker plot of fragments per kilobase of transcript per million mapped reads 
(FPKM) expression values for LSD1 across different TCGA datasets. Box limits are set at 
the third and first quartile range with central line at the median, with whiskers depicting 1.5 
times the interquartile range. Datapoints outside this range are represented at outliers (black 
dots). Black and blue outline indicates data for WT and PIK3CA mutant tumors, 
respectively. Red and purple fill represent significant increase and decrease in LSD1 
expression, respectively, between PIK3CA mutant and PIK3CA WT tumors. The numbers 
under the box plots are the number of samples used to generate the plots. Western blot 
analysis of empty vector (shEV) or LSD1 KD in (B) SW480 or (C) HT29 cells. Arrow head 
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indicates correct position of pT308-AKT band. Western blot quantified by densitometric 
analysis and normalized to β-actin and shEV. Results are represented as mean ± SD. (N=3). 
Significance was determined by two-tailed Student’s t-test. LSD1 CRISPR KO clones with 
or without LSD1 OE plasmid (HA-LSD1) in (D) SW480 or (E) HT29 cells analyzed by 
western blot. (F) EV, LSD1 KD or LSD1 OE cells treated w/ 250 μM H2O2 for 1H. (G) 
Brightfield and immunofluorescence images of EV or LSD1 KD HT29 cells under untreated 
or H2O2 treated conditions. A field was selected in the H2O2 treated shLSD1 cells to 
facilitate direct comparison of LSD1 deficient and LSD1 proficient cells. White arrow 
indicates cells with LSD1 expression and orange arrow indicates cells deficient in LSD1. (p-
value; ***<.001, ****<.0001, ns - not significant).
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Figure 2: LSD1 catalytic activity is dispensable for regulation of gene expression and activation 
of AKT.
(A) Metageneplot and heatmap depicting ChIP-seq of LSD1 in WT (N=2) or LSD1 KO 
(N=1) SW480 cells at gene enrichment sites genome-wide. Average plots and heatmaps 
depicting: (B) LSD1 enrichment peak overlap with DNase-seq peaks in SW480, and (C) 
H3K4me2 ChIP-seq signal at TSS enrichment sites genome-wide in shEV and shLSD1 
SW480 cells (N=3). (A-C) Values are derived from CPM (counts per million) normalized 
reads. (E) Differentially expressed genes (DEGs) from RNA-seq (log2FC>=1 & FDR<=0.05 
= purple) after 40 nM GSK-LSD1 for 48H vs. DMSO or shLSD1 vs shEV in SW480 cells 
(N=3). (D) ChIP-seq gene tracks of representative DEGs in LSD1 versus EV KD SW480 
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cells with or without LSD1 promoter enrichment. (F) Cells pretreated with DMSO or 40 nM 
GSK-LSD1 for 48H then treated with 250 μM H2O2 for 1H. Western blots were quantified 
by densitometric analysis and normalized to loading control and DMSO. Graph represents 
mean ± SD. ns – not significant. Significance determined using one-way ANOVA with 
Tukey’s multiple comparisons test (N=3). (G) Mixed population LSD1 KO cells were 
transfected with vector control, HA-LSD1, or HA-LSD1(K661A) for 48H. Whole cell 
extract from untreated and cells treated with 250 μM H2O2 for 1H were analyzed by western 
blot.
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Figure 3: LSD1 regulates AKT activation via scaffolding of the CoREST complex on chromatin.
(A) Chromatin affinity assay performed in shEV or shLSD1 with whole cell extract (WCE) 
or chromatin bound fraction. Western blots were quantified by densitometric analysis and 
normalized to loading control and shEV fraction. Significance determined by 2way ANOVA 
with Sidak’s multiple comparisons test (N=3). Graphs depict mean ± SD (adj. p-value; **<.
01, ****<.0001, ns – not significant). (B) shEV or shRCOR1 cells treated with 250 μM 
H2O2 for 1H, and analyzed by western blot. (C) shEV or shHDAC1 cells treated as in B. (D) 
Model for corin inhibitor mode of action. (E) Cells treated with DMSO or 3, 5 or 7 μM corin 
over time course, and analyzed by western blot. (F) Box and whisker plot of fragments per 
kilobase of transcript per million mapped reads (FPKM) expression values for RCOR1 
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across different TCGA datasets. Box limits are set at the third and first quartile range with 
central line at the median, with whiskers depicting 1.5 times the interquartile range. 
Datapoints outside this range are represented as outliers (black dots). Black and blue outline 
indicates data for WT and PIK3CA mutant tumors, respectively. Red fill represent 
significant increase in LSD1 expression, respectively, between PIK3CA mutant and PIK3CA 
WT tumors. (G) Fraction of patients with PIK3CA mutation separated by high expression of 
LSD1 or RCOR1 vs low expression of both LSD1 and RCOR1. Plotted below is 
bootstrapped 90% confidence interval for the difference in fraction for patients with the 
PIK3CA mutation between the two groups. Significance determined by permutation test (p-
value; ***< 0.001).
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Figure 4: Gastrointestinal cell lines with mutant PIK3CA are sensitive to LSD1 KD.
(A) SW480, LoVo, HT29, AGS, HCT116 and RKO cell growth over a five-day time course 
determined by the CellTiter-Glo Luminescent Cell Viability Assay. N=4. Graph depicts 
mean + SD. Statistical analyses are performed using 2way ANOVA and Sidaks multiple 
comparisons test with all statistically significant comparisons shown. adj. p-value; **<.01, 
****<.0001. (B) Correlation plot of RNA-seq data from LSD1 versus EV KD in SW480 and 
HT29 cells. Significant data points are defined as abs(Log2FC)>=1 & FDR<=0.05 for LSD1 
compared to EV KD for each cell line, including those unique to HT29 (purple), unique to 
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SW480 (red), and shared between HT29 and SW480 (black). N=3. (C) Ridge plot depicts 
LSD1 versus EV KD expression changes of genes contributing to max enrichment score of 
hallmark and curated gene sets accessed from the molecular Signatures Database (v6.2). 
GSEA Ratio shows the ratio of genes contributing to max enrichment score, to the total 
number of genes in the gene set. Heatmap on right shows Log2FC value for each gene 
enriched in HALLMARK_PI3K_AKT_MTOR_SIGNALING in either HT29 or SW480 
cells sorted by HT29 Log2FC. (D) Network analysis of uniquely upregulated genes in HT29 
after LSD1 KD with significantly enriched processes from the Reactome database. Similar 
terms were manually grouped, and size and color of circles were set to indicate number of 
genes and the p-value, respectively. (E) Clonogenic growth assay. Significance determined 
by 2way ANOVA with Sidak’s multiple comparisons test. N = 3. Results are represented as 
mean ± SD. adj. p-value; **<.01, ns – not significant.
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Figure 5: LSD1 regulates Snail stability via AKT in PIK3CA C2 domain mutant cancer cells.
(A) Western blot analysis of HT29 or (B) AGS cells treated with DMSO or 10 μM 
GSK690693 for 48H. (C) Real-time PCR analysis of SNAI1 RNA expression levels after 
48H DMSO or 10 μM GSK690693 treatment in HT29 and AGS cells. Expression was 
normalized to Gapdh and DMSO. Results are represented as mean ± SD. Significance 
determined by 2way ANOVA with Sidak’s multiple comparisons test. ns – not significant. 
(D) Proportion of total PIK3CA mutations occurring in the different domains indicated 
across various cancer types in the TCGA pancancer datasets. (E) shEV and shLSD1 HT29 
cells treated with DMSO or 10 μM MG-132 for 4H and analyzed by western blot. (F) Real-
time PCR analysis of LSD1 and SNAI1 RNA expression levels in shEV and shLSD1 HT29 
cells as in (C). adj. p-value; ****<.0001. (G) HT29 shLSD1 cells were transfected with HA-
LSD1 alone or in combination with 10 μM GSK690693.
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Figure 6: LSD1 is required for EGF-induced migration of cells with an active AKT-GSK3β-Snail 
axis.
(A) 10x bright field images of crystal violet stained HT29 cells after 48H migration through 
transwell insert. WT, LSD1 KO, 10 μM GSK690693 or 3 μM corin cells were co-treated 
with 100 ng/mL EGF for 48H. (B) Quantification of migration normalized to migration 
counts for untreated cells. Results are represented as mean ± SD. Significance was 
determined by one-way ANOVA with Tukey’s multiple comparisons test. All significant 
comparisons are shown. adj. p-value; ****<.0001. (C) shEV or shLSD1 cells were treated 
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with 100 ng/mL EGF for 24H or 48H and analyzed by western blot. (D) Model depicting 
CoREST complex in the regulation of AKT.
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